JUNS - Latest News

Jupiter Neurosciences, Inc. (JUNS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $8.7M. Beta to the broader market is 2.14.

The article list below shows the most recent JUNS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent JUNS Headlines

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

globenewswire.com - May 27, 2026

Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

accessnewswire.com - May 26, 2026

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biophar

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

globenewswire.com - May 21, 2026

Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE)

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

globenewswire.com - May 20, 2026

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceut

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

benzinga.com - May 20, 2026

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.

How News Affects JUNS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track JUNS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked JUNS news questions

What is the latest JUNS news headline?

The most recent JUNS headline (May 27, 2026) is "Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the JUNS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What JUNS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual JUNS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.